Sensorion Provides 2016 Financial Calendar

Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today published its financial calendar for 2016.

In addition to these periodic announcements, investors can consult the Company’s website (www.sensorion-pharma.com) where information is updated on a regular basis. All corporate and financial information on the Company is available on it’s website in the Investors section.

* Dates of the company’s scheduled announcements are subject to change.

???

About Sensorion

Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop three drug candidate programs for treating the symptoms of vertigo and tinnitus, for preventing complications associated with progressive lesions in the inner ear, and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion has a portfolio of 7 patent families, employs 16 staff and receives financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative. Sensorion is listed on Alternext Paris since April 2015. www.sensorion-pharma.com

Name: SENSORION
ISIN code: FR0012596468
Ticker: ALSEN

View source version on businesswire.com: http://www.businesswire.com/news/home/20160208005991/en/